ENDRA Life Sciences Inc.
NDRA
$6.46
$1.1922.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.25M | 1.40M | 1.11M | 938.60K | 920.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.48M | 2.17M | 1.62M | 1.37M | 1.30M |
| Operating Income | -1.48M | -2.17M | -1.62M | -1.37M | -1.30M |
| Income Before Tax | 159.90K | -1.31M | -3.17M | -1.60M | -1.23M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 159.90K | -1.31M | -3.17M | -1.60M | -1.23M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 159.90K | -1.31M | -3.17M | -1.60M | -1.23M |
| EBIT | -1.48M | -2.17M | -1.62M | -1.37M | -1.30M |
| EBITDA | -1.48M | -2.16M | -1.61M | -1.36M | -1.29M |
| EPS Basic | 0.12 | -1.09 | -2.85 | -2.10 | -1.71 |
| Normalized Basic EPS | 0.07 | -0.69 | -1.79 | -1.31 | -1.07 |
| EPS Diluted | 0.06 | -1.09 | -2.85 | -2.10 | -1.71 |
| Normalized Diluted EPS | 0.04 | -0.69 | -1.79 | -1.31 | -1.07 |
| Average Basic Shares Outstanding | 1.32M | 1.20M | 1.11M | 761.20K | 717.10K |
| Average Diluted Shares Outstanding | 2.48M | 1.20M | 1.11M | 761.20K | 717.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |